Optimizing antibody expression by using the naturally occurring framework diversity in a live bacterial antibody display system
Bispecific antibodies have gained increased relevance in research and therapeutic settings despite the complexities in their production and challenges in finding the right combination.
The presentation will discuss strategies and consideration to screen for the best bispecific antibody pair.
In addition, a novel approach to produce a bispecific antibody with natural architecture in a single cell will be discussed. The technology now simplifies bispecific production for research and development.
Clinical update: targeting DLL4 and Notch 2/3 to inhibit tumors
An update on OncoMed’s clinical development of antibodies targeting DLL4 and Notch2/3
Blocking DLL4 has been shown in preclinical studies to result in anti-tumor activity via multiple mechanisms, including inhibiting cancer stem cell growth and promoting cell differentiation, disrupting angiogenesis and potentially enhancing anti-tumor immune response.
Tarextumab (anti-Notch2/3, OMP-59R5) is a novel anti-cancer stem cell antibody that prevents signaling through both the Notch2 and Notch3 receptors. Tarextumab has been shown in preclinical models to inhibit cancer stem cell growth, and promote cell differentiation, as well as disrupt tumor angiogenesis by inhibiting vascular pericytes.